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DOI 10.1016/j.ccr.2012.01.007SUMMARYPancreatic ductal adenocarcinomas (PDAs) are characterized by a robust fibroinflammatory response. We
show here that this desmoplastic reaction generates inordinately high interstitial fluid pressures (IFPs),
exceeding those previously measured or theorized for solid tumors, and induces vascular collapse, while
presenting substantial barriers to perfusion, diffusion, and convection of small molecule therapeutics. We
identify hyaluronan, or hyaluronic acid (HA), as the primary matrix determinant of these barriers and show
that systemic administration of an enzymatic agent can ablate stromal HA from autochthonous murine
PDA, normalize IFP, and re-expand the microvasculature. In combination with the standard chemothera-
peutic, gemcitabine, the treatment permanently remodels the tumor microenvironment and consistently
achieves objective tumor responses, resulting in a near doubling of overall survival.INTRODUCTION
Pancreatic ductal adenocarcinoma (PDA) is the fourth leading
cause of cancer-related deaths in the United States (Jemal
et al., 2010). The inherent biology of the disease makes it not
only uniformly but also rapidly lethal: overall 5-year survival for
PDA is less than 5%, with a median survival of 4–6 months
(Hidalgo, 2010). Gemcitabine, a deoxycytosine analog, repre-
sents the current standard of care for advanced disease and
improves quality of life in a minority of patients while prolonging
survival by several weeks (Burris et al., 1997). A recent advance
involving targeted inhibition of epidermal growth factor receptor
(EGFR) with erlotinib extends median survival by an additional
14 days (Moore et al., 2007). Moreover, despite notable
advances in surgical technique and postoperative care, and
the use of adjuvant chemical and radiotherapies, virtually allSignificance
More than 90% of cancer drugs brought to the clinic fail. The g
part, from the inability of traditional model systems to sufficient
tumor ‘‘organ.’’ In failing to fully account for the tremendous obs
tunities to identify and target themost clinically meaningful bar
matrix glycosaminoglycan fortifies the epithelium and create
renders the cancer profoundly vulnerable to standard cytotoxic
compelling reassessment of conventional chemotherapies pre
418 Cancer Cell 21, 418–429, March 20, 2012 ª2012 Elsevier Inc.early-stage patients who undergo resection also eventually
succumb to recurrent and/or metastatic disease (Allison et al.,
1998; Farnell et al., 2005; Oettle et al., 2007). Understanding
the unusual resistance of pancreas cancer and finding ways to
treat it at all stages of disease are clear and imperative needs.
Most preclinical drug evaluations to date have relied on in vitro
assays and in vivo cell transplantation models. However, tumor
cells arising in situ in the native organ are categorically distinct
from the same cells grown in culture or engrafted into an immu-
nocompromised mouse (Bissell and Radisky, 2001). Indeed,
transplanted pancreas carcinoma cells respond readily to
conventional chemotherapeutic agents (Hertel et al., 1990), in
marked contrast to autochthonous tumors in mice (Olive et al.,
2009) and humans (Tempero et al., 2003). This problem cuts
both ways: in failing to fully appreciate the unique challenges
imposed by the complex cancer ‘‘organ,’’ opportunities to targetap between preclinical promise and clinical reality arises, in
ly represent the cellular and structural complexity of the solid
tacles to efficacy in autochthonous tumors, potential oppor-
riers are also lost. We have found that an unusually abundant
s a drug-free sanctuary in PDA. Ablating this constituent
s and holds promise as a distinct therapeutic strategy, while
viously thought to be ineffective.
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missed. Thus, there are noncell autonomous factors, including
unique cell-cell and cell-matrix interactions and evolving intratu-
moral physical dynamics, that contribute to the in vivo resistance
of cancers.
Prior work in a number of experimental systems has sug-
gested that altered intratumoral fluid dynamics can limit the
effectiveness of systemic therapies (reviewed in Bouzin and
Feron, 2007; Heldin et al., 2004; Jain, 1987; Tre´dan et al.,
2007). Mammalian organs and tissues typically possess intersti-
tial fluid pressures (IFPs) at or below the intravascular pressures
(IVPs) in the terminal arterioles and capillaries that supply
them. As first proposed by Starling in 1896, an IFP less than
IVP permits ready perfusion and favors diffusive and convective
forces necessary for solute and fluid flow into the interstitium
(Starling, 1896; see Supplemental Information available online).
The solutes are consumed by cells, while the venous vasculature
and functional lymphatic channels return excess fluid to the
systemic circulation (reviewed in Michel, 1984). Although these
processes governing the delivery and diffusion of cancer drugs
have been studied extensively in xenograft models, very few
experiments have been performed in autochthonous carci-
nomas, and no rigorous analyses before and after perturbation
of the tumor microenvironment have been described.
PDAs are characterized by an unusually intense desmoplastic
reaction composed of fibroblasts, immune cells, and endothelial
cells embedded within a dense and complex extracellular matrix
(ECM). The ECMcomponent hyaluronic acid (HA), or hyaluronan,
is inordinately abundant, inviting speculation on its role in
disease biology and resistance. HA is a large linear glycosamino-
glycan (GAG), composed of repeating N-acetyl glucosamine and
glucuronic acid units, and figures prominently in the architecture,
integrity, and malleability of tissues, particularly in dynamic
processes such as embryogenesis and oncogenesis (Toole,
2004). Its viscoelastic properties underlie its unique role in tissue
homeostasis and its appeal in cosmetic and clinical applications
(Balazs and Denlinger, 1989). HA also communicates directly
with cells in health and disease through interactions with several
distinct types of surface receptors. However, the abundance of
HA varies widely across tumors, and it has been shown to both
promote and suppress tumor growth (Toole, 2004). Even its
potential contribution to IFP is controversial. Local injection of
hyaluronidase into osteosarcoma xenografts has been shown
to decrease IFP (Brekken et al., 2000; Eikenes et al., 2005),
although enforced overexpression of HA in thyroid and colon
carcinoma xenografts did not increase it (Jacobson et al.,
2003). Thus, although HA has been implicated in a variety of
cell autonomous and noncell autonomous processes, its precise
role(s) in therapeutic resistance of cancers has remained elusive
and is likely context specific (reviewed in Toole and Slomiany,
2008; Tre´dan et al., 2007).
As an alternative to transplanted cells and tumors, we have
developed genetically engineered mouse (GEM) models of
PDA that faithfully recapitulate the clinical syndrome, histopa-
thology, and molecular progression of human pancreas cancer
from inception to invasion. KrasLSL-G12D/+;Cre (KC) (Hingorani
et al., 2003) and KrasLSL-G12D/+;Trp53LSL-R172H/+;Cre (KPC) (Hin-
gorani et al., 2005) mice conditionally express endogenous,
physiologic levels of the respective oncogene and tumorsuppressor genemutations in pancreatic progenitor cells, result-
ing in the stochastic development and spontaneous progression
of preinvasive ductal lesions to invasive and metastatic carci-
nomas. In collaborative studies using the KPC model, we have
recently suggested that the unusually hypovascular microenvi-
ronment of PDA compromises the delivery of even small
molecule therapeutics such as gemcitabine. These studies
showed further that targeting stromal fibroblasts by disrupting
paracrine Hedgehog signaling between the epithelial and
mesenchymal tumor compartments transiently increased the
apparent microvascular density through neoangiogenesis and
improved drug delivery, resulting in a modest survival benefit
(Olive et al., 2009). Interestingly, disease resistance rapidly re-
emerged along with a return of the profound hypovascularity.
Moreover, the mechanisms giving rise to and sustaining this
paucity of vessels remained unclear. In the present study, we
pursue a mechanistic understanding of the biophysical barriers
to perfusion, diffusion, and convection imposed by the desmo-
plastic reaction in autochthonous PDA and investigate strategies
to surmount them.
RESULTS
Cellular and Molecular Evolution of Desmoplasia in PDA
As part of a systematic effort to characterize the evolving stromal
dynamics and potential therapeutic vulnerabilities during
disease progression, we performed specific histochemical and
immunohistochemical assays to identify components of the
ECM and infiltrating cells in preinvasive, invasive, andmetastatic
PDA in mice and humans (Figure 1 and Figures S1A–S1D). A
robust and definable stromal reaction develops in association
with early precursor lesions and includes a dense collagen
content organized in a fibrillary structure in both primary tumors
and metastases, as revealed by intravital second harmonic
generation (SHG) imaging (Figures S1E–S1J). The tight
association of this fibrillar collagen with epithelial carcinoma
cells became evident in KrasLSL-G12D/+;Trp53LSL-R172H/+;
R26LSL-GFP/+;Cre (KPGC) mice. Interestingly, the relative con-
centrations of collagen and glycosaminoglycans (GAGs) appear
to alter during disease progression, shifting toward higher GAG
content at more advanced and metastatic stages of disease
(Figures 1A–1J). One particular GAG, HA, was especially abun-
dant (Figures 1K–1O), which was confirmed by treating tissue
sections with hyaluronidase (Figures S1K–S1N). We note that
significant HA deposition begins with early precursor lesions
(Figures 1G and 1L). In addition, activated stromal pancreatic
stellate cells (PSCs), or myofibroblasts, also infiltrate early and
are prevalent throughout disease progression (Figures 1P–1T).
Conversely, a decrease in vessel number is seen with progres-
sion (Figures S1O–S1Q), as described previously (Olive et al.,
2009), and is accompanied by a decrease in cross-sectional
(luminal) area (Figure S1R).
This same overall molecular and cellular stromal composition
is observed in human PDA (Figures 1E, 1J, 1O, and 1T). We
note, in particular, the expression of moderate-to-high levels
of HA in all human PDAs tested (n = 30; Figures 1J and 1O
and data not shown), suggesting that this substrate may be
an essential component of disease architecture, biology, and
resistance.Cancer Cell 21, 418–429, March 20, 2012 ª2012 Elsevier Inc. 419
Figure 1. Evolution of the Desmoplastic Reaction in Murine and Human PDA
(A–E) Masson’s trichrome histochemistry shows robust collagen deposition (blue) at all stages of disease.
(F–J) Movat’s pentachrome histochemistry reveals collagen (yellow), GAGs and mucins (blue), and their colocalization (turquoise/green).
(K–O) Histochemistry with HA-binding protein (HABP) reveals intense HA content beginning with preinvasive disease (PanIN).
(P–T) Activated PSC express a-smooth muscle actin (a-SMA) and are abundant in preinvasive (Q), invasive (R) and metastatic mPDA (S) and hPDA (T), but not in
normal pancreata (P). ac, acini; is, islet; d, duct; v, venule; h, hepatic parenchyma; *, metastatic lesions. Scale bars, 25 mm. See also Figure S1.
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To directly measure IFP in normal pancreata and in autochtho-
nousPDAs in live animals, we used a systemcoupling aminiature
piezoelectric pressure transducer to a pressure control unit and
data acquisition module (Figure 2A). Anesthetized animals
underwent laparotomy followed by needle-guided placement
of the pressure transducer probe enabling real-time in vivo IFP
measurements (Figures 2B and 2C). As expected, the normal
pancreas possesses an IFP ranging between 8 and 13 mm Hg
(mean = 10.4mmHg; n = 8) (Figure 2D). In contrast, we observed
dramatically elevated IFPs in autochthonous PDA that far ex-
ceeded the normal range for the pancreas (Figure 2D). Tumor
IFPs ranged from 75 to 130 mm Hg (mean = 99 mm Hg, n = 7,
in KPC PDA; mean = 87 mm Hg, n = 4, in KC tumors), which
vastly exceeded typical arteriolar and capillary pressures of
40–80 mm Hg and 15–40 mm Hg, respectively (Sherwood,
1997) and rivaled mean arterial pressure (Janssen et al., 2000;
Mattson, 1998). Pressures of this magnitude suggest not only
major impediments to delivery and convection of small mole-
cules, but also imply a profound reorganization and remodeling
of the tumor architecture and the forces operant within it (see
also Supplemental Information).420 Cancer Cell 21, 418–429, March 20, 2012 ª2012 Elsevier Inc.Enzymatic Targeting of Stromal HA Restores Tumor IFP
and Functional Perfusion
We began our studies on the ability of HA to elevate IFP using
reconstituted three-dimensional matrices. Purified primary
murine PDA cells were embedded in matrices with differing HA
concentrations, the tumor plugs were implanted in immunodefi-
cient mice, and IFPs were recorded (Figures S2A–S2C). HA
concentrations of 3 mg/ml more than doubled the baseline IFP
of carcinoma cells engrafted in collagen alone, suggesting that
the presence of HA in the tumor can contribute directly to
elevated IFP.
The abundance of HA in PDA and its demonstrated capacity to
significantly elevate IFP prompted us to investigate whether a
systemically delivered agent could ablate HA in the stroma of
an autochthonous PDA and decrease pressures. We first tested
the ability of intravenously administered PEGPH20 to deplete HA
from normal tissues in wild-type (WT) mice and assessed for any
untoward effects (Figures S2D–S2F). Several organs in the body
including heart, lung, bowel, and liver contain modest levels of
detectable HA (Figure S2E), whereas joints possess very high
levels (Figure S2F). HA was efficiently ablated from all of these
sites except cartilage and the surrounding joint space. Cartilage
Figure 2. Elevated IFP Compromises
Vascular Function in PDA
(A) Experimental apparatus to measure IFP.
(B and C) IFP probe positioned in PDA at the head
of the pancreas (hp). In (B), the probe ends in
a tumor obscured by the overlying liver.
(D) IFP measurements in normal pancreata (N),
untreated KPC and KC tumors and tumors 2 and
24 hr after PEGPH20 treatment. *p < 0.01 for
comparison between normal pancreata and
PEGPH20 treatment groups; **p < 0.05 for differ-
ence from all other groups with 1-way ANOVA and
Newman-Keuls posthoc multiple comparison test.
Note that IFP levels in normal pancreata and
PEGPH20-treated KC (mean = 16 mm Hg, n = 4)
and KPC (mean = 22 mm Hg, n = 5) tumors 24 hr
after treatment were not statistically different. Box
and whisker plots: boxes display the lower (25th)
and upper (75th) quartiles with a line at the median;
whiskers extend from the minimum to the
maximum observation.
(E–G) Distribution of CD31+ vessel diameter in
normal pancreata (E), untreated KPC tumors (F),
and KPC tumors 24 hr after PEGPH20 treatment
(G). Insets show data for vessels of diameter >
10 mm. Data represent evaluations from four
independent sections from each of four separate
animals for each condition and are significantly
different (p < 0.0001) in the pairwise comparisons
with KPC.
(H–J) Multiphoton excitation of fluorescently
conjugated lectin (red) and second harmonic
generation imaging of collagen (green) within
intact normal pancreas (H), untreated KPC tumors
(I), and KPC tumors 24 hr after PEGPH20 treat-
ment (J). Asterisks in (H) and (J) highlight examples
of large functional vessels. Arrows in (I) and (J)
indicate perfused (functional) vessels. Note that
when a rare functional vessel in untreated KPC
tumors is identified, it is extremely small relative to
those in normal pancreata and PEGPH20 treated
tumors. Scale bar, 10 mm for (H–J).
(K–M) Direct fluorescence analysis of Alexa-647-conjugated lectin (red) and doxorubicin (green) in intact normal pancreas (K), untreatedKPC tumors (L), andKPC
tumors 24 hr after PEGPH20 treatment (M). Arrow in (K) shows an example of a widely patent, thin-walled vessel, and arrowheads indicate ductal epithelium.
Large arrows in (L) and (M) highlight regions magnified in respective inset boxes. The left inset box in (L) shows signal in the far-red Alexa-647 channel (lectin)
alone, and the right inset box shows merged green (doxorubicin) and red (lectin) channels. Small arrows in inset box of panel (M) identify examples of specific
nuclear staining from DNA-bound doxorubicin, as well as the presence of free doxorubicin in the tumor. Asterisks in (M) highlight examples of large, functional
lectin-positive vessels loaded with doxorubicin. ac, acini; is, islet; d, duct. Scale bar, 50 mm for (K–M). See also Figure S2.
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excluding delivery of PEGPH20. Interestingly, depletion of HA
from these sites had no discernible effects on organ function
or animal health; animals remained active without apparent
changes in energy level or mobility and also maintained their
body weight (Figure S2D). We next demonstrated that in-
travenous administration of PEGPH20 to KC and KPC mice
could deplete HA in autochthonous PDAs (Figure S2G). More-
over, after a single intravenous dose of PEGPH20, IFP was
significantly decreased within 2 hr and approached the range
for normal pancreata 24 hr after treatment (Figure 2D). The
restoration of near normal tumor IFP after degradation of
stromal HA suggested that treatment with PEGPH20 should
also significantly and rapidly improve blood flow if indeed
mechanical compression of the vasculature was the primary
mechanism limiting perfusion. To assess the effects on thetumor microvasculature of IFP normalization, we performed
a systematic survey of vessel number and lumen diameter in
WT pancreata as well as untreated and treated murine PDA
(Figures 2E–2G). We found a significant shift in the distribution
of CD31+ vessel diameters in murine and human PDA com-
pared with the normal pancreas and, in particular, an almost
complete absence of large diameter (>10 mm) vessels (Figures
2E–2G and Figures S2H and S2I). The normal pancreas
contains a range of small-to-moderate sized vessels, more
than 80% of which possess a readily discernible and patent
lumen; conversely, the majority (75%) of vessels in PDA
lacked an apparent lumen, consistent with vascular collapse
from elevated extrinsic fluid pressures. Following treatment
with PEGPH20, vessel diameter was significantly increased
and lumens clearly discernible in 71% of CD31+ vessels (Fig-
ure 2G and Figure S2H).Cancer Cell 21, 418–429, March 20, 2012 ª2012 Elsevier Inc. 421
Figure 3. Gemcitabine+PEGPH20 Combination
Therapy Fundamentally Changes the Tumor
Vasculature
(A) Treatment schedule for administration of PEGPH20 (P) or
placeboandgemcitabine (G).Miceundergoing gemcitabine
monotherapy also received placebo (vehicle) injections.
Each 4-week course represents one cycle of therapy.
(B) Tumor IFP at survival endpoint after treatment with
gemcitabine (G; n = 9) or Gem+PEGPH20 (GP; n = 9), *p <
0.0001. Box and whisker plots: boxes display the lower
(25th) and upper (75th) quartiles with a line at the median;
whiskers extend from the minimum to the maximum
observation.
(C) Gross pathology of transected PDA at endpoint after
gemcitabine monotherapy. d, duodenum.
(D) Gross pathology of transected PDA at endpoint after
combination therapy.
(E and F) Distribution of significantly different (p < 0.0001)
CD31+ vessel diameter in Gem (E) and Gem+PEGPH20 (F)
treated KPC tumors at survival endpoint. Inset graphs
show significantly different (p < 0.0001) distribution also
for subsets of vessels with diameters between 10–20 mm
and > 20 mm. Data are from four independent sections
from five separate animals for each treatment arm. See
also Figure S3.
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intravital multiphoton laser scanning microscopy (MPLSM).
Normal pancreata revealed a rich, widely patent vasculature
(Figure 2H) with excellent delivery of the small molecule thera-
peutic doxorubicin throughout the parenchyma (Figure 2K). In
contrast, vessels in PDA were difficult to detect and appeared
collapsed (Figure 2I), and penetration of doxorubicin into the
tumor bed was extremely limited (Figure 2L). Even when rare
perfusion was observed (Figure 2L), the distribution of drug
into the tumor was low, suggesting limited diffusion and convec-
tion into the interstitium. A single intravenous dose of PEGPH20
resulted in the immediate appearance of significant numbers of
patent vessels (Figures 2J and 2M), reflecting their increased
diameters (Figure 2G). These changes were accompanied by
a >6.5-fold increase in doxorubicin fluorescence intensity over
baseline (p = 0.013, n = 4 each for treated and untreated KPC
cohorts; and p = 0.04, n = 3 per group for KC PDAs). We note
that overall vessel number did not significantly change (data
not shown), which, together with the rapidity of the effect and
lack of significant endothelial cell proliferation (see below),
suggest that neoangiogenesis did not contribute substantively.
Rather, it appears that the inordinately high IFP produces
vascular collapse in PDA and reversal of these elevated pres-422 Cancer Cell 21, 418–429, March 20, 2012 ª2012 Elsevier Inc.sures restores functional perfusion and unim-
peded delivery of drug into the carcinoma.
Combined Enzymatic and Cytotoxic
Chemotherapy Alters Tumor Biology and
Increases Disease Response
and Overall Survival in PDA
We next sought to assess the effects of combi-
nation chemotherapy on the gross morpholog-
ical, physicomechanical, cellular, andmolecular
properties of autochthonous PDA. In previousstudies of gemcitabine in KPC mice (Olive et al., 2009), we
used a dose, route, and schedule modeled on the original
preclinical investigations of gemcitabine in subcutaneously en-
grafted tumors (Hertel et al., 1990; Schultz et al., 1993). For the
present studies, we treated KPC cohorts according to the route
and schedule used in the clinic. Specifically, we performed
a randomized, placebo-controlled study of the combination
regimen involving intravenous drug administration in cycles con-
sisting of the 3-weeks ‘‘on’’ and 1-week ‘‘off’’ schedule used in
patients (Figure 3A). Animals were first assessed with serial
high-resolution ultrasound measurements until they achieved
a requisite enrollment tumor diameter of 2–5 mm. Studies were
performed on separate cohorts of animals to measure early
and intermediate effects, and also to establish overall survival.
As expected, IFP normalized in Gem+PEGPH20-treated
tumors, confirming that the addition of gemcitabine did not
impede the ability of PEGPH20 to influence this physicomechan-
ical property (Figure 3B). Interestingly, no change in baseline
tumor IFP occurred in Gem+Placebo-treated animals, reflecting
the inability of gemcitabine to effectively penetrate tumors and
induce responses. The gross findings at necropsy underscored
these differences, as tumors recovered from Gem+Placebo-
treated animals (Figure 3C and Figure S3A) revealed the hard,
Figure 4. Gemcitabine+PEGPH20 Induces Objec-
tive Responses through Reduced Proliferation
and Increased Apoptosis
(A) High-resolution ultrasound images of PDA before and
after the indicated treatment. Scale bar, 1 mm. t, tumor.
(B) Quantitative analysis of tumor volume in Gem (G; n = 5)
and Gem+PEGPH20 (GP; n = 6) treated mice after one
cycle of therapy (*p = 0.009). Box and whisker plots: boxes
display the lower (25th) and upper (75th) quartiles with a line
at the median; whiskers extend from the minimum to the
maximum observation.
(C) Quantitative analysis of proliferation assessed as
percentage of Ki-67+ cells per image field in untreated (U)
and Gem (G) or Gem+PEGPH20 (GP) treated tumors after
either two weekly doses of therapy (2 Dose; *p < 0.035) or
at endpoint (End; *p = 0.0009).
(D) Quantitative analysis of apoptosis assessed as
percentage of cleaved caspase-3 (CC3)+ cells per image
field in untreated (U) and Gem (G) or Gem+PEGPH20 (GP)
treated tumors after two doses of therapy (*p = 0.035) or at
endpoint (*p = 0.01). Data in (C and D) are plotted as
mean ± SEM. See also Figure S4.
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the untreated disease (Figure S3B). In contrast, tumors from
animals receiving Gem+PEGPH20 were notably soft, highly
vascularized, and even hemorrhagic when transected (Fig-
ures 3D and Figures S3C–S3F). A blood-rich microenvironment
in combination treated tumors was readily apparent even by
routine histology (Figures S3G–S3L). Quantitative analysis
confirmed significant differences in vessel diameter between
Gem+Placebo- and Gem+PEGPH20-treated PDA (Figures 3E
and 3F) without significant differences in vessel number (data
not shown). Importantly, these findings were observed in all
mice immediately after initiating therapy (Figures S3G–S3L),
during active treatment (Figures S3M and S3N), and persisted
even after treatment cessation (Figures S3O–S3T). Even nearly
3 months after completing combination therapy, functional
vessels were retained suggesting an irreversible change in tumor
physiology (Figures S3S and S3T).
Objective measures of clinical response were frequently
apparent after only one cycle of combination therapy. Notably,
of the subset of Gem+Placebo-treated animals that underwent
quantitative volumetric imaging both before and after treatment,
none experienced an objective tumor response affirming the
collective clinical (Burris et al., 1997; Casper et al., 1994) and
preclinical experience with this agent in autochthonous PDA
(Olive et al., 2009) (Figures 4A and 4B). In contrast, 83% of Gem+Cancer Cell 21, 4PEGPH20-treated tumors decreased in size
after one cycle of treatment (Figures 4A and
4B) with all tumors responding after three cycles
(see example in Figure S4A). Consistent with its
known mechanisms of inhibiting DNA and RNA
synthesis (Hertel et al., 1990; Ueno et al., 2007),
combination therapy both decreased prolifera-
tion and increased apoptosis of primary tumor
cells comparedwithGem+Placebo, contributing
to the observed differences in objective re-
sponses (Figures 4C and 4D and Figures S4B–
S4E). Thus, when able to penetrate the tumorbed, gemcitabine can indeed be an effective agent against this
disease.
The numbers of total stromal PSCs (Figure S5A) and activated
PSCs (Figures 5A–5C and Figure S5B) were also significantly
decreased, and the tumor stroma was extensively remodeled
(Figures 5D–5G). Although unaffected by PEGPH20 alone,
collagen content and distribution were both significantly
decreased by the combined regimen, likely as a secondary
consequence of depleting collagen-secreting activated PSCs.
Finally, no discernible effects on endothelial cell proliferation
(Figure S5C) or apoptosis (Figure S5D) were observed, consis-
tent with the expected restricted activity of a conventional cyto-
toxic agent to actively dividing cells. Thus, the depleted HA and
diminished IFP seen with the combined enzymatic and cytotoxic
regimen restores and preserves a functional vasculature while
inducing tumor epithelial and stromal cells to die.
Similar restrictions and responses were observed in metas-
tases. Metastatic lesions to the liver (Figures 1D, 1I, 1N, and 1S)
and lung (Figure 6A) possessed a robust and complex desmopla-
sia, with notable HA content and a paucity of vessels (Figures
S6A–S6G). Perhaps surprisingly, given their typically smaller size
compared with primary tumors, the metastatic deposits were
also poorly perfused by small molecules (Figures S6H–S6K). As
with primary tumors, PEGPH20efficiently ablatedHA frommetas-
tases (Figure 6B) and restored functional perfusion (Figure S6K).18–429, March 20, 2012 ª2012 Elsevier Inc. 423
Figure 5. Combination Therapy with Gemcitabine+
PEGPH20 Remodels the Tumor Stroma
(A and B) IHC for the PSC activation marker a-SMA in PDA at survival endpoint after the indicated treatment. Scale bar, 50 mm.
(C) Quantitative analysis of PSC activation in untreated tumors (U) or tumors treated with Gem (G), PEGPH20 (P), or Gem+PEGPH20 (GP) at survival endpoint
(*p = 0.005).
(D and E) Representative micrographs from intravital SHG imaging of collagen (green) combined with multiphoton excitation of endogenous fluorescence from
NADH (red) in PDA at survival endpoint just prior to euthanasia. Scale bar, 50 mm.
(F) Mean SHG intensity in PDAs at endpoint as a measure of fibrillar collagen concentration (*p = 0.028).
(G) Percent area occupied by fibrillar collagen in tumors at endpoint (*p = 0.028). Data in (C), (F), and (G) are plotted as mean ± SEM. See also Figure S5.
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decreased proliferation (Figure 6C) and increased apoptosis (Fig-
ure 6D) in metastases to both distant sites.
The aforementioned encouraging results notwithstanding,
the most clinically relevant measure of efficacy is survival. We
therefore performed a prospective, randomized, placebo-
controlled trial in KPC mice with overall survival as the primary
endpoint. Secondary endpoints included changes in intratu-
moral IFP and objective response rates, as well as metastatic
disease burden.
Median overall survival increased from 55.5 days for Gem+
Placebo to 91.5 days for Gem+PEGPH20, an 83% increase (Fig-
ure 6E). These results likely do not reflect themaximal achievable
benefit from combination therapy as the treatment course was
limited to 3 months because of sclerosing of the vein after
repeated intravenous injections. In fact, only 29% of Gem+
PEGPH20-treated animals died during the course of therapy
andapproximately 30%ofanimals livedanadditional 4–11weeks
after completing three full months of treatment. In contrast, more
than 80% of animals receiving Gem+Placebo died during treat-
ment; of the remaining four animals, three died in the very next
week after cessation of therapy (Figure 6E and Table S1).424 Cancer Cell 21, 418–429, March 20, 2012 ª2012 Elsevier Inc.Themetastatic tumor burden was also significantly diminished
with combination therapy (Figure 6F, Table 1, and Table S1). The
frequency of malignant ascites as well as metastases to the liver,
lungs, diaphragm, and mesenteric lymph nodes were all
decreased in the Gem+PEGPH20 cohort. Thus, the combination
regimen effectively treated both the primary and metastatic
disease burdens.
DISCUSSION
The defining features of PDA are a penchant for metastatic
spread and a notorious resistance to chemical and radiother-
apies. These features, in turn, establish the major hurdles to
meaningful treatment of the disease. A perhaps prosaic, albeit
unexpected and critically important, barrier to systemic therapy
is a profoundly diminished functional vasculature in PDA. We
show here that the primary mechanism limiting perfusion in
PDA is significant collapse of resident vessels by inordinately
high fluid pressures. Small molecules that are delivered to the
tumor bed are subsequently impeded from penetrating the inter-
stitium by constraints on diffusion and convection, completing
a trifecta of stromal barriers to chemotherapy. Enzymatic
Figure 6. Gemcitabine+PEGPH20 Combination
Therapy Decreases Metastatic Tumor Burden and
Improves Survival
(A and B) HA expression in lung metastases from
untreated (A) and PEGPH20-treated (B) animals.
(C) Quantitative analyses of proliferation assessed as
percentage of Ki-67+ cells in metastases to liver (filled
circles) and lung (open squares) after gemcitabine mon-
otherapy (G) or Gem+PEGPH20 (GP) combination therapy
(p = 0.0012). Horizontal bars represent means.
(D) Quantitative analysis of apoptosis assessed as
percentage of CC3+ cells in liver (filled circles) and lung
(open squares) metastases (p = 0.0001). Horizontal bars
represent means.
(E) Kaplan-Meier survival curves from time of enrollment in
control (Con; n = 16), Gem (n = 16), PEGPH20 (n = 15), and
Gem+PEGPH20-treated KPC animals (n = 14). (Black bar
indicates maximum duration of therapy.) Median overall
survival of Gem (55.5 days) and Gem+PEGPH20
(91.5 days) treated mice are significantly different (*p =
0.004). Treatment with PEGPH20 alone showed a trend
toward increased survival (median = 63 days) that did not
reach statistical significance (p = 0.1).
(F) Metastatic burden in Gem+PEGPH20 (GP) treated
mice is significantly decreased compared with Gem
treatment alone (G) (*p = 0.014). See also Figure S6 and
Table S1.
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accompanied by the appearance of widely patent functioning
vessels. Removing these barriers permits high concentrations
of chemotherapy to reach the tumor, resulting in improved
survival and revealing an unappreciated sensitivity of the disease
to conventional cytotoxic agents.
The theory governing the movement of fluid and solute across
a semipermeable membrane dividing two compartments (e.g.,
vascular and extravascular) is readily derived from fundamental
thermodynamic principles (Kedem and Katchalsky, 1958;
Kedem and Katchalsky, 1961; Staverman, 1952) (reviewed in
Ogston and Michel, 1978) and incorporates hydrostatic and
osmotic pressure gradients as the primary determinants of fluid
flow, and concentration gradients as the driving force for solute
flux. The resultant equations, in turn, explain the inability to
achieve effective chemotherapy concentrations in PDA given
the extremely high IFPs observed (see Supplemental Information
for a detailed treatment of these equations). They do not,
however, adequately address how such dramatically elevated
IFPs arise in the first place. The prevailing hypotheses envision
the intravascular and interstitial compartments to be in contiguity
or communication, suggesting that changes in IFP chronicle and
directly reflect intratumoral vascular pressures largely as
a consequence of ‘‘leaky’’ or damaged vessels (Boucher and
Jain, 1992; Netti et al., 1999). However, the essentially completeCancer Cell 21, 4collapse of the microvasculature in invasive
PDA implies that this relationship no longer
holds and that forces other than intravascular
pressure must be maintaining the dramatically
elevated IFP. Indeed, we have observed a sus-
tained elevation of tumor IFP even after the
cessation of cardiac function (unpublishedobservations), underscoring the disconnect between intravas-
cular pressure and IFP in this setting. Some models also postu-
late an elevated interstitial permeability in tumors (Jain, 1990),
which appears not to be the case in PDA and, in any event, would
favor not hinder delivery of (macro)molecules. Thus, despite an
extensive history of studies in experimental systems and limited
work in human cancers in situ (Boucher et al., 1991; Curti et al.,
1993; Less et al., 1992), themagnitude of interstitial hypertension
in solid tumors has clearly been underestimated, particularly with
respect to PDA, and the mechanisms driving its genesis have
remained elusive.
Plausible mechanisms to further elevate interstitial pressure
include an ECM production sufficiently prolific to increase tumor
density more rapidly than volume, and/or robust cell contractility
that actively compacts the tumor (Reed et al., 1992). In this
regard, the ability of a systemically delivered enzyme to dissipate
the high IFPs in PDA not only holds great therapeutic promise but
also provides insight into the underlying physicomechanical
processes operant within this complex cancer environment
(Figure 7). Intact HA functions as a hydrated gel generating an
immobile fluid phase that secondarily also diminishes compress-
ibility (tethered collagen fibers under tension provide the primary
framework for rigid structure). We propose that PEGPH20 first
liberates water bound to HA through cleavage of the extended
polymer into substituent units. The release of trapped water18–429, March 20, 2012 ª2012 Elsevier Inc. 425
Table 1. Summary of Metastatic Disease Burden in KPC Mice
Treatment
Mice with
Metastatic
Disease (%)
No. of
Macroscopic
Metastases/
Mouse
(mean ± SEM)
No. of
Metastases/
Mouse
(mean ± SEM)
Mice with
Liver
Metastases (%)
Mice with
Lung
Metastases (%)
Mice with
Diaphragm
Metastases (%)
Mice with
Lymph Node
Involvement (%)
Mice with
Malignant
Ascites (%)
Gem+Placebo 93 1.7 ± 0.35 2.4 ± 0.35 73 40 40 73 47
Gem+PEGPH20 43 0.86 ± 0.4 1.1 ± 0.4 43 21 21 36 21
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collapsed arterioles and capillaries to open. Without additional
treatment, HA is replenished, in part by a-SMA(+) myofibro-
blasts, and intratumoral physical dynamics are restored.
Together with a concomitant cytotoxic agent, however, the
resultant death of activated PSC leads to the additional loss of
collagen I content through decreased synthesis, while also un-
raveling its architecture, which itself has been implicated in
promoting carcinoma invasion and metastasis (Provenzano
et al., 2006; Wang et al., 2002), impeding drug delivery (Eikenes
et al., 2004; Netti et al., 2000; Ramanujan et al., 2002), and
conferring gemcitabine resistance (Dangi-Garimella et al.,
2011). Thus, enzymatic degradation of HA removes the central
barrier, allowing drugs to breach the previously impenetrable
sanctuary of PDA. A subsequent feed-forward mechanism
results in depletion of stromal fibroblasts and carcinoma cells,
dissolution of the collagen network, and irrevocable remodeling
of the tumor microenvironment. Uniform objective responses
ensue, at least until cells can evolve secondary mechanisms of
resistance. This gap in time represents an unprecedented
opportunity for therapeutic advantage. The persistence of patent
vessels enables switching sequentially from one chemothera-
peutic regimen to another in hopes of prolonging this window
of vulnerability. In this context, revisiting the extensive list of
previously presumed ‘‘ineffective’’ agents against PDA (Nieto
et al., 2008) represents an obvious starting point, even as
additional targets within the tumor stroma are identified and
explored (Izeradjene and Hingorani, 2007).
In the context of our current findings, two very recent reports of
combination regimens to treat advanced PDA are particularly
notable for their shared pharmacokinetic features and their
improved success over the current standard. One regimen
combined gemcitabine with nab-paclitaxel, an albumin-coated
formulation of taxol with an extended half-life of >10 hr in
the circulation (Von Hoff et al., 2011). A second regimen,
FOLFIRINOX, added bolus dosing of two conventional cytotoxic
agents onto a base of prolonged (46 hr) continuous infusion of
fluorouracil with each treatment cycle (Conroy et al., 2011). In
each case, the sustained exposure to cytotoxic therapy may
have helped surmount the relative barriers to perfusion imposed
by the ECM of PDA.
Finally, the prospect that augmenting blood flow to a lethal
carcinoma may increase its ability to seed metastatic deposits
gives pause; however, the dramatically decreased metastatic
tumor burden in animals treated with combination therapy is re-
assuring and no doubt contributes to the observed benefit in
overall survival. Indeed, that Gemcitabine+PEGPH20 improves
survival in animals with advanced andmetastatic disease under-
scores its potential utility for the majority of patients who present426 Cancer Cell 21, 418–429, March 20, 2012 ª2012 Elsevier Inc.with PDA. These findings also reflect the similar physicochemical
principles operant in metastases as in the primary tumor; in fact,
our molecular characterization of the ECM suggests that the
metastatic microenvironment is further enriched in GAGs
(including HA) relative to collagen as compared with primary
tumors. Understanding the precise mechanism of achieving
a decreasedmetastatic tumor burden has important implications
for specific clinical uses of PEGPH20. The decreased metastatic
burden may have been achieved by regression of established
metastases (which we have observed) and/or decreased seed-
ing of metastases either by killing primary tumor cells or altering
their ability to spread. HA has been directly implicated in
increasing the metastatic potential of cancer cells (Zhang
et al., 1995). However, HA depletion may also inhibit the ability
of already seeded cells to establish clinically relevant metas-
tases. In other words, HAmay represent a necessary component
of the microenvironmental niche in order for a circulating tumor
cell or nest of cells to blossom fully into a life-limiting lesion.
Thus, there may be additional potential uses for and benefits
from a stromal targeting therapy including, for example, as part
of an adjuvant regimen. Given that more than two thirds of
patients with resected PDA eventually succumb to metastatic
disease (Hidalgo, 2010), incorporating an enzymatic agent that
degrades HA in the adjuvant setting may extend survival by
preventing, or at least delaying, the establishment of a critical
metastatic disease burden.
EXPERIMENTAL PROCEDURES
Mouse Strains
All animal studies were approved by the Institutional Animal Care and Use
Committee of the Fred Hutchinson Cancer Research Center. KrasLSL-G12D/+;
Trp53LSL-R172H/+;Cre (KPC)mice have been previously described in detail (Hin-
gorani et al., 2005). KPC mice conditionally express endogenous physiologic
levels of activated Kras and point mutant Trp53 targeted to progenitor cells
of the developing pancreas. The animals spontaneously develop the full spec-
trum of precursor ductal lesions (pancreatic intraepithelial neoplasias, PanINs)
which progress to invasive andmetastatic PDA, faithfully mimicking the clinical
syndrome, histopathology, and molecular progression of the human disease
from inception to invasion and metastasis. A subset of experiments were
also performed on KrasLSL-G12D/+;Cre (KC) mice, which similarly develop inva-
sive and metastatic disease along the PanIN-to-PDA progression scheme,
albeit with a slower time course than KPC mice (Hingorani et al., 2003).
ROSA26LSL-EGFP mice (obtained from Jackson Laboratory) contain enhanced
green fluorescent protein (EGFP) cDNA sequence flanked by LoxP sites
knocked-in to the ROSA26 locus.
Measuring Interstitial Fluid Pressure
Interstitial fluid pressure (IFP) measurements were performed using a Millar
Mikro-Tip pressure catheter transducer (SPR-1000, 0.33 mm diameter) with
a dynamic pressure range from 50 to 300 mm Hg, possessing a shielded
side-mounted sensor. The catheter was connected to PCU-2000 Pressure
Figure 7. Altering Physicomechanics and Remodeling the Stroma in PDA to Therapeutic Advantage
(A) Intratumoral mechanics in PDA impede diffusion and convection of small molecules.
(B) Enzymatic degradation of stromal HA decreases IFP and relieves physical constraints on small molecule perfusion, which can reconstitute in the absence of
additional therapy.
(C) Combined enzymatic and cytotoxic therapy permanently remodels the tumor microenvironment to favor the delivery and distribution of small molecules.
Blue spheres represent chemotherapy molecules, vessels are shown in red, carcinoma cells in light blue, activated PSC in brown, collagen in green, and HA in
yellow. Pi, interstitial fluid pressure; Pv, intravascular fluid pressure. See text for details.
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Instruments, Inc.) (Ozerdem and Hargens, 2005; Thompson et al., 2010). Data
were recorded and analyzed using LabChart software (Millar Instruments,
Inc.). The system was calibrated to 0, 25, and 100 mm Hg prior to each
measurement following the manufacturer’s recommendations; calibration
was reconfirmed after each study. To place the microtip pressure catheter,
a 25-gauge needle (23 the diameter of the probe) was first introduced into
the tissue or tumor of interest, and the probe was inserted into the space after
needle withdrawal.
Assessment of Vascular Function and Molecular Diffusion
Toassess vascular function, 425ml of biotin-conjugated Lycopersiconesculen-
tum lectin (B1175-1mg, Vector Laboratories) was mixed with 75 ml of Strepta-
vidin-AlexaFluor-488 (S32354, Molecular Probes) for whole-tissue MPLSM
imaging or with Streptavidin-AlexaFluor-647 (S21375) for analyses of tissue
sections following coadministration of doxorubicin (Sigma). Mice were anes-
thetized by inhalation of isofluorane gas. Five minutes prior to euthanasia,
100ml of the conjugated lectinwasadministered into the left ventricle. For coad-
ministration experiments, 20mg/kg doxorubicin solution was injected immedi-
ately after fluorescently conjugated lectin. While under terminal anesthesia,
mice were perfused with 4% paraformaldehyde. For histologic analyses,
harvested tissues were additionally fixed overnight in 4% paraformaldehyde.
Treatment Schedule and Survival Study
Enrollment of KPC mice was based on primary tumor burden and informed
by age. Specifically, animals 12–14 weeks old and with a palpable pancreas
mass were enrolled. Ultrasound imaging was performed in the initial 11 miceenrolled to confirm the physical examination findings of estimated tumor
burden. KPC mice were genotyped and then randomized by one investigator
(A.E.C.) to receive Gemcitabine+Placebo or Gemcitabine+PEGPH20, which
were administered by another investigator (P.P.P.). Objective response was
assessed by high-resolution ultrasound performed by a third investigator
(C.C.) who was blinded to the treatments administered. The treatment
schedule was modeled on the standard clinical management of patients
with pancreas cancer (Figure 3A). Gemcitabine was administered intrave-
nously (i.v.) once weekly at 50 mg/kg in a three weeks on/one week off
schedule; PEGPH20 (or vehicle) was administered i.v. 24 hr prior to
gemcitabine.
Statistical Analyses
Data were tested to determine whether they met the assumption of normality
using the Kolmogorov-Smirnov test. Normally distributed two-group data
were analyzed using a t test. Multigroup data were analyzed using ANOVA fol-
lowed with the Newman-Kuels multiple comparison post test. In the instance
that two-group data did not conform to normality, the nonparametric Mann-
Whitney sum rank test was performed. Kaplan-Meier survival data were
analyzed using a log rank test. Metastatic disease burden was analyzed using
Fisher’s exact test.
SUPPLEMENTAL INFORMATION
Supplemental Information includes six figures, one table, and Supplemental
Experimental Procedures and can be found with this article online at
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